AddLife AB
STO:ALIF B
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
AddLife AB
Income from Continuing Operations
AddLife AB
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
AddLife AB
STO:ALIF B
|
Income from Continuing Operations
kr562m
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
BICO Group AB
STO:BICO
|
Income from Continuing Operations
-kr1.6B
|
CAGR 3-Years
-162%
|
CAGR 5-Years
-100%
|
CAGR 10-Years
N/A
|
|
|
A
|
AroCell AB (publ)
STO:AROC
|
Income from Continuing Operations
-kr12.2m
|
CAGR 3-Years
41%
|
CAGR 5-Years
13%
|
CAGR 10-Years
-5%
|
|
|
Biotage AB
STO:BIOT
|
Income from Continuing Operations
kr255m
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
G
|
Genovis AB
STO:GENO
|
Income from Continuing Operations
kr23.5m
|
CAGR 3-Years
28%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
MedCap AB (publ)
STO:MCAP
|
Income from Continuing Operations
kr220.7m
|
CAGR 3-Years
23%
|
CAGR 5-Years
28%
|
CAGR 10-Years
35%
|
|
AddLife AB
Glance View
AddLife AB, a prominent player in the life sciences sector, intricately weaves its narrative through a commitment to enhancing healthcare and laboratory services across Europe. Founded in Sweden, the company has established itself as a crucial intermediary, effectively bridging the gap between manufacturers of medical devices and the healthcare institutions that require them. AddLife operates by acquiring and developing niche companies within two core segments: Labtech and Medtech. Through Labtech, it supplies essential equipment, instruments, and consumables for diagnostic and research laboratories. In Medtech, it provides a variety of healthcare logistics, medical products, and services to hospitals and care facilities, enhancing their operational efficiencies. The financial heartbeat of AddLife rests on its adeptness at creating value through strategic acquisitions and organic growth, capitalizing on the increasing demand for innovative healthcare solutions. By continuously expanding its product portfolio and enhancing the capabilities of its subsidiaries, AddLife ensures a diversified revenue stream, mitigating risks associated with dependence on any single product or market. This approach not only fortifies their market position but also fuels their profit margins, as they deftly respond to shifting industry demands and regulatory changes. The company's shared values and decentralized business model promote entrepreneurship within its subsidiaries, fostering an environment where innovation can thrive—ensuring their continued success and substantial contribution to the evolving landscape of healthcare.
See Also
What is AddLife AB's Income from Continuing Operations?
Income from Continuing Operations
562m
SEK
Based on the financial report for Dec 31, 2025, AddLife AB's Income from Continuing Operations amounts to 562m SEK.
What is AddLife AB's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
2%
Over the last year, the Income from Continuing Operations growth was 121%. The average annual Income from Continuing Operations growth rates for AddLife AB have been 5% over the past three years , 2% over the past five years .